Core tip: customers are the foundation of the long-term survival and development of Tu enterprises
Analysis of advantages and disadvantages of ultrasonic liposuction
Time of Update: 2020-04-03
Many plastic surgeons tend to use ultrasound liposuction for people who need a large area of fat removal because it bleed about 50% less than other liposuction techniques.
Yutong's brilliant debut at China International Maritime Exhibition 2019
Time of Update: 2019-12-09
Facing the future, Yutong Co., Ltd. will pay more attention to technological innovation, shipowner's demand, product quality and technical service, and actively lead the development of China's ship anti-corrosion coating.
NEJM news: combined immunotherapy significantly improves the long-term survival rate of melanoma patients
Time of Update: 2019-10-17
October 17, 2019 / bioun / - according to a study by the NHS Foundation in Royal Marsden, a combination of two immunotherapeutic drugs, ipilimumab and nivolumab, has prevented
Listed pharmaceutical companies want to buy hospitals, but also need calm objective analysis
Time of Update: 2019-08-20
[pharmaceutical network market analysis] with the continuous promotion of policies such as the separation of pharmaceutical companies and the two vote system, many pharmaceutical
[field view] Zhang Zhefeng: analysis of the basis of drug research and development from the perspective of technical review
Time of Update: 2019-07-08
Therefore, when improving drugs, we need to evaluate the establishment of benign innovation, research and development ideas from these aspects, that is, what is the goal of improvement?
Yaoming biology and NBE company of Switzerland establish a comprehensive cooperation in ADC drug development and production
Time of Update: 2019-04-09
April 9, 2019 / AP / -- the world's leading open platform company of biopharmaceutical technology, Yaoming biology, and NBE therapeutics, a Swiss innovative biopharmaceutical
Dinghang pharmaceutical and HTG molecular diagnostics signed a cooperation agreement to jointly develop new technologies of tumor immunotherapy
Time of Update: 2018-08-06
August 3, 2018 / Meitong news agency / -- oncologie, an innovative Biomedical Company based in Boston, USA and Shanghai, China, and HTG molecular, a NASDAQ listed company
Three minefields should be avoided in the upgrading and transformation of pharmaceutical machinery enterprises: price war, fake innovation and old routine
Time of Update: 2018-07-31
However, in the process of upgrading and transformation, pharmaceutical machinery enterprises need to avoid three minefields: price war, pseudo innovation and old routines.
Chinese scientists discover a new tool for tumor immunotherapy
Time of Update: 2018-04-10
The reporter learned from Suzhou Institute of nanotechnology, Chinese Academy of Sciences that the cancer diagnosis and treatment team led by researcher Zhu Yimin of the Institute
The results showed that the combination therapy of multiple drugs had significant therapeutic effect on chronic lymphocytic leukemia
Time of Update: 2017-12-20
Recently, a clinical trial ( showed that targeted therapy composed of three drugs ( has significant therapeutic effect on chronic lymphocytic leukemia (CLL), and can reduce the long-term negative effect caused by chemotherapy.
Long term strategic cooperation between Kangmei pharmaceutical and BGI
Time of Update: 2017-11-09
[China Pharmaceutical network enterprise news] on the evening of October 31, Kangmei pharmaceutical industry announced that the company signed a strategic cooperation agreement
"Healthy Jilin 2030" plan outline released
Time of Update: 2017-06-06
[policies and regulations of China Pharmaceutical network] recently, the outline of "healthy Jilin 2030" issued by Jilin Province proposed that by 2030, we should transform from
Sun Xiaobo: clinical effect is the material basis for the long-term development of traditional Chinese Medicine
Time of Update: 2017-03-28
[expert opinion of chinapharma.com] on March 14, three senior experts in the field of medicine and general health, sun Xiaobo, Wang Fengqi and Shang Qi, participated
